Thermo Fisher Scientific Inc. (TMO) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $531.67. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TMO = $554.60 (+4.3% from the current price, the stock appears fairly valued). Analyst consensus target is TMO = $651 (+22.4% upside).
Valuation: TMO trades at a trailing Price-to-Earnings (P/E) of 28 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.03.
Financials: revenue is $44.6B, -0.2%/yr average growth. Net income is $6.7B, growing at -0.6%/yr. Net profit margin is 15.1% (healthy). Gross margin is 37.7% (-5.7 pp trend).
Balance sheet: total debt is $40.9B against $53.4B equity (Debt-to-Equity (D/E) ratio 0.76, moderate). Current ratio is 1.89 (strong liquidity). Debt-to-assets is 37%. Total assets: $110.3B.
Analyst outlook: 38 / 42 analysts rate TMO as buy (90%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 36/100 (Fail), Growth 15/100 (Fail), Past 100/100 (Pass), Health 67/100 (Partial), Moat 61/100 (Partial), Future 94/100 (Pass), Income 70/100 (Pass).
